Zentalis Pharmaceuticals (ZNTL) grants CLO 100,000 stock options award

Rhea-AI Filing Summary

Zentalis Pharmaceuticals reported an equity award to its Chief Legal Officer, James B. Bucher. He received a stock option grant covering 100,000 shares of common stock at an exercise price of $2.84 per share. The options were granted on January 8, 2026 and are held directly. Following this grant, Bucher beneficially owns 100,000 stock options.

The options will vest over four years in substantially equal monthly installments, and vesting is conditioned on his continued service with the company. This is a compensatory award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bucher James B

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	100,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 100,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bucher James B

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.84	01/08/2026		A		100,000		(1)	01/07/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ James B. Bucher	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zentalis Pharmaceuticals (ZNTL) disclose for James B. Bucher?

Zentalis Pharmaceuticals disclosed that Chief Legal Officer James B. Bucher received a grant of 100,000 stock options on January 8, 2026.

What are the key terms of James B. Bucher’s stock options at Zentalis (ZNTL)?

The stock options give Bucher the right to buy 100,000 shares of common stock at an exercise price of $2.84 per share and expire on January 7, 2036.

How do the Zentalis (ZNTL) stock options granted to James B. Bucher vest?

The options will vest over four years in substantially equal monthly installments, subject to Bucher’s continued service with Zentalis Pharmaceuticals.

Is the Zentalis (ZNTL) transaction a purchase, sale, or grant of derivatives?

It is a grant of derivative securities, specifically a compensatory stock option (right to buy) for 100,000 shares at $2.84 per share.

How many Zentalis (ZNTL) derivative securities does James B. Bucher own after this grant?

After the reported grant, James B. Bucher beneficially owns 100,000 stock options directly.

Did James B. Bucher pay anything for the Zentalis (ZNTL) stock option grant?

The filing shows a price of $0 for the derivative security, indicating the options were granted as compensation rather than purchased in the market.